Mycorena, a Swedish mycoprotein company, has been acquired by Naplasol, part of the VEOS Group, marking a significant step in the company’s development. Established in 2017, Mycorena has focused on fungi-based technology, producing its signature product, Promyc®, known for its nutritional value and sustainable production. This acquisition allows Mycorena to scale its operations with the support of Naplasol’s industrial infrastructure in Belgium. While the integration into the VEOS Group brings new opportunities, Mycorena’s core mission of advancing sustainable food production through innovative mycoprotein solutions remains unchanged. The transition reflects the broader industry’s shift towards more sustainable protein alternatives.
Mycorena develops innovative fungi technology to provide next-generation food ingredients. Its flagship product, Promyc®, is a nutritious and sustainable mycoprotein. The quality of Promyc® is unique in terms of its neutral taste and strong fibrous texture.
Prior to its acquisition by Naplasol, Mycorena AB filed for bankruptcy on July 10th, citing insurmountable financial challenges despite significant efforts to sustain operations. The Swedish mycoprotein company, known for its innovative fungi fermentation technology and its flagship product Promyc®, faced difficulties securing new lead investors amid tough financial market conditions.
This led to the difficult decision to restructure under new ownership. Despite these setbacks, Mycorena’s leadership remains hopeful that the company’s extensive expertise and valuable assets, including a robust patent portfolio and advanced production facilities, has attracted a buyer capable of continuing its mission to lead in sustainable food production.
“Both companies, Naplasol and Mycorena, are active in the same field and have complementary knowledge and products of which we can benefit in the future,” says Wim Slee, co-CEO of VEOS Group. “We are proud that we can continue the story of Mycorena, as we strongly believe in the future of mycoproteins. Mycoproteins are clearly a sustainable protein alternative, with a lower CO2, land and water footprint compared to other plant-based proteins,” continues Wim Slee.
“Mycorena has been on an exciting journey toward becoming a leading player in the mycoprotein industry. The acquisition and merger with Naplasol offer a unique opportunity to build on the foundation we have established. We look forward to seeing Mycorena continue to thrive under the strong industrial expertise of the Veos Group,” says Ramkumar Nair PhD, Founder of Mycorena.
Click here to read more IPO/M&A news.
Read the orginal article: https://arcticstartup.com/mycorena-acquired-by-naplasol/
